Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Protollin · 1 trial · 1 indication
Safety and tolerability of ascending doses of nasal Protollin following administration of two doses one week apart in subjects, 60-85 years inclusive with Early Symptomatic Alzheimer's Disease (29-20 MMSE classification). Safety will be assessed by physical examination (including evaluation of the nose and oropharynx), laboratory studies, EKG, and elicited and spontaneously reported signs and symptoms, using the FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (September 2007) for the evaluation of toxicities and reactogenicity. Tolerability will be assessed by the degree of severity of both spontaneously reported and elicited symptoms and associated signs, systemically and at the site of administration following administration of nasal Protollin, if thought by the investigator to be related or possibly related to its administration.
| Arm | Type | Description |
|---|---|---|
| Cohort A | ACTIVE_COMPARATOR | Protollin 0.1 mg or placebo |
| Cohort B | ACTIVE_COMPARATOR | Protollin 0.5 mg or placebo |
| Cohort C | ACTIVE_COMPARATOR | Protollin 1.0 mg or placebo |
| Cohort D | ACTIVE_COMPARATOR | Protollin 1.5 mg or placebo |
| Name | Type | Description |
|---|---|---|
| Protollin | DRUG | For the 0.1, 0.5, and 1.0 mg dose groups, Protollin (450 μL per vial) in an aqueous buffer will be administered in two, 0.1 μL sprays, one per nostril. For the 1.5 mg dose group, Protollin (450 muL per vial) in an aqueous buffer will be administered in three, 0.1 μL sprays, two in one nostril and one in the other nostril. |
Inclusion Criteria: 1. The Sponsor will rely on NIA-AA Alzheimer's Disease Diagnostic Guidelines1 for Early Symptomatic Alzheimer's Disease and have a MMSE of 29-20. 2. Age between 60-85 years (inclusive). 3. Good general health with no disease expected to interfere with the study. 4. On a stable m...
Top 20 of 24 competitors
Protollin is an investigational small molecule being studied for the treatment of early symptomatic Alzheimer's Disease (AD). It is administered nasally and is currently in Phase 1 clinical development. Protollin is not yet approved by the FDA and remains under investigation for this indication.
Protollin is being developed by I-Mab, which is listed as a Sponsored ADR on the stock exchange under the ticker NBP. The company is conducting clinical research on this investigational drug for Alzheimer's Disease.
Protollin is in Phase 1 clinical development for Alzheimer's Disease. A Phase 1 trial has been completed, involving 16 participants. The drug is still investigational and has not received FDA approval.
Protollin has one completed Phase 1 trial, identified as NCT07187141, titled 'Nasal Protollin in Early Symptomatic Alzheimer's Disease.' This trial enrolled 16 participants in the United States, all aged 60 years or older, and was randomized, double-blind, and active-controlled.
No alternative names for Protollin have been reported. It is identified solely by the name Protollin in clinical trial records and development information.